Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study

CONCLUSION: Second-line camrelizumab combined apatinib and chemotherapy might serve as a potential treatment with acceptable safety in patients with advanced LUAD.PMID:37956490 | DOI:10.1016/j.intimp.2023.111147

Source: International Immunopharmacology - November 13, 2023 Category: Allergy & Immunology Authors: Yiwei Yao Yong Wang Yingying Du Fengshou Jiang Hui Liang Minghong Bi Hua Xie Wanren Peng Yueyin Pan Source Type: research